Acknowledgment: The authors thank Amanda M. Gutierrez, Jeremiah Lee, Anveet S. Janwadkar, and Bharath M. Ram for research assistance and Richard T. Brandt and John Minser for REDCap support.
Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that her spouse has stock options/holdings with Targeted Diagnostics and Therapeutics. Darren B. Taichman, MD, PhD, Executive Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Christina C. Wee, MD, MPH, Deputy Editor, reports employment with Beth Israel Deaconess Medical Center. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Yu-Xiao Yang, MD, MSCE, Deputy Editor, reports that he has no financial relationships or interest to disclose.
Reproducible Research Statement: Study protocol: Available from Dr. Antommaria (e-mail,
[email protected]).
Statistical code: Not available.
Data set: Available from Dr. Gibb (e-mail,
[email protected]).
Corresponding Author: Armand H. Matheny Antommaria, MD, PhD, Ethics Center, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, ML 15006, Cincinnati, OH 45229; e-mail,
[email protected].
Current Author Addresses: Dr. Antommaria: Ethics Center, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, ML 15006, Cincinnati, OH 45229.
Dr. Gibb: Program in Medical Ethics, Humanities and Law, Western Michigan University Homer Stryker M.D. School of Medicine, 1000 Oakland Drive, Kalamazoo, MI 49008.
Dr. McGuire: Center for Medical Ethics and Health Policy, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030.
Dr. Root Wolpe: Center for Ethics, Emory University, 1531 Dickey Drive, Atlanta, GA 30322.
Dr. Wynia: Center for Bioethics and Humanities, University of Colorado Anschutz Medical Campus, 13080 East 19th Avenue, Room 201E, Mail Stop B137, Aurora, CO 80045.
Dr. Eberl: Albert Gnaegi Center for Health Care Ethics, Saint Louis University, 3545 Lafayette Avenue, Salus Center 501, St. Louis, MO 63104.
Dr. Applewhite: Center for Medical Ethics Education and Research, Albany Medical College, 50 New Scotland Avenue, MC 193, Albany, NY 12211.
Drs. Caplan and Schiff: Division of Medical Ethics, NYU School of Medicine, 227 East 30th Street, 7th Floor, New York, NY 10016.
Dr. Diekema: Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research Institute, 1900 Ninth Avenue, JMB-6, Seattle, WA 98101.
Dr. Hester: Department of Medical Humanities & Bioethics, UAMS College of Medicine, 4301 West Markham Street, 646, Little Rock, AR 72205.
Drs. Tabor and Wieten: Center for Biomedical Ethics, Stanford University School of Medicine, 1215 Welch Road, Modular A, Stanford, CA 94305.
Dr. Lehmann: VA New England Healthcare System, 200 Springs Road, Bedford, MA 01730.
Author Contributions: Conception and design: A.H. Antommaria, T.S. Gibb, A.L. McGuire, P. Root Wolpe, M. Wynia, A.L. Caplan, D.S. Diekema, R. McLeod-Sordjan, H. Tabor, J.T. Eberl.
Analysis and interpretation of the data: A.H. Antommaria, T.S. Gibb, A.L. McGuire, M. Wynia, A.L. Caplan, D.M. Hester, L. Lehmann, R. McLeod-Sordjan, T. Schiff, H. Tabor, S.E. Wieten, J.T. Eberl.
Drafting of the article: A.H. Antommaria, T.S. Gibb, A.L. McGuire, P. Root Wolpe, M. Wynia, A.L. Caplan, J.T. Eberl.
Critical revision for important intellectual content: A.H. Antommaria, T.S. Gibb, A.L. McGuire, P. Root Wolpe, M. Wynia, A.L. Caplan, L. Lehmann, J.T. Eberl.
Final approval of the article: A.H. Antommaria, T.S. Gibb, A.L. McGuire, P. Root Wolpe, M. Wynia, M.K. Applewhite, A.L. Caplan, D.S. Diekema, D.M. Hester, L. Lehmann, R. McLeod-Sordjan, T. Schiff, H. Tabor, S.E. Wieten, J.T. Eberl.
Provision of study materials or patients: M. Wynia, M.K. Applewhite, D.S. Diekema.
Statistical expertise: T.S. Gibb.
Administrative, technical, or logistic support: A.H. Antommaria, T.S. Gibb, A.L. McGuire, P. Root Wolpe, A.L. Caplan, S.E. Wieten, J.T. Eberl.
Collection and assembly of data: A.H. Antommaria, T.S. Gibb, A.L. McGuire, P. Root Wolpe, M. Wynia, M.K. Applewhite, A.L. Caplan, D.S. Diekema, D.M. Hester, L. Lehmann, H. Tabor, J.T. Eberl.
This article was published at
Annals.org on 24 April 2020.
* For members of a Task Force of the Association of Bioethics Program Directors, see the
Appendix.
Intensive Care Unit Triage Protocols: A Case for Inclusivity and Engagement in COVID-19
As patient partners who live with chronic illness and with lived experiences in intensive care units (ICUs), we compliment the authors for studying triage policies at various institutions in North America. This study provides a timely and essential review of elements related to discrimination, exclusion criteria and community engagement that must be considered during the coronavirus disease (COVID-19) pandemic. We were concerned by the findings, specifically, that disability was not well-considered by various healthcare authorities in determining access to ICU services. The paper highlighted that 46.2% of all policies use specific clinical diagnosis in allocating treatment resources and only 26.9% of policies indicated that decisions should not be based on disability. There is not sufficient evidence identifying a correlation between comorbidities and poor outcomes after COVID-19 diagnosis. The exclusion criteria established by healthcare institutions result in decisions to deny care to those with pre-existing conditions. These decisions are not based in evidence and are in fact discriminatory.[1]
We were also concerned with the lack of community engagement in the development of the ICU triage policies identified in this study. The authors highlighted that only 7.7% of hospitals engaged community members as part of the triage team. Community engagement is crucial to ensure diverse perspectives are heard and incorporated into the development of hospital policies in the support of justice and fairness. The World Health Organization has published a Risk Communicate and Community Engagement Action Plan that emphasizes the need for community stakeholders to be involved in decisions during the COVID-19 pandemic.[2] Procedural fairness and natural justice require that members of groups potentially affected have a right to be heard and to be part of policy and other decisions made about medical care.[3] Policy development and triage committees must be accountable for these decisions and transparency is imperative.
We are certain that justice isn’t served when these avenues of communication are closed. These hospital policies systematically disadvantage people with disabilities in allocating healthcare resources.[4] Over 15% of the global population has a disability and yet this group is inadequately recognized and protected.[5] Too quickly we forget that people with disabilities are a part of our society, community, workplace and families. We thank the authors for reminding the medical field and policy makers of the essential elements that must be considered during the COVID-19 pandemic.
1. Andersen L, Proulx L, Sirotich E. Are intensive care triage protocols harming the disabled? The BMJ Opinion. 21 May 2020. Accessed at https://blogs.bmj.com/bmj/2020/05/21/are-intensive-care-triage-protocols-harming-the-disabled/
2. World Health Organization. Risk Communication and Community Engagement (RCCE) Action Plan Guidance COVID-19 Preparedness and Response. 16 March 2020. Accessed at https://www.who.int/publications-detail/risk-communication-and-community-engagement-(rcce)-action-plan-guidance
3. Persad G. What Is the Relevance of Procedural Fairness to Making Determinations about Medical Evidence? AMA J Ethics. 2017;19(2):183-191. doi: 10.1001/journalofethics.2017.19.2.pfor1-1702.
4. Armitage R, Nellums LB. The COVID-19 response must be disability inclusive. Lancet Public Health. 2020;5(5):e257. doi:10.1016/S2468-2667(20)30076-1
5. World Health Organization.World Report on Disability. 13 December 2011. Accessed at https://www.who.int/disabilities/world_report/2011/report/en/
Disclosures:
ES is a Board Member of the Canadian Arthritis Patient Alliance, a patient run, volunteer-based organization whose activities are largely supported by independent grants from pharmaceutical companies. LP has received speaking fees of less than $500 from a pharmaceutical company. LP is the 2nd Vice President of the Canadian Arthritis Patient Alliance, a patient run, volunteer-based organization whose activities are largely supported by independent grants from pharmaceutical companies Lene Andersen is an author and disability rights advocate. She has received consulting fees of less than $2000 from pharmaceutical companies.